Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines

References

• Valavanidis A, Vlachogianni T. Engineered nanomaterials for pharmaceutical and biomedical products new trends, benefits and opportunities. Pharm Bioprocess. 2016;4:13.
   Google Scholar
• Dublin TD. Research policy. Am J Public Heal Nations Heal. 1959;49:265–268. doi:10.2105/AJPH.49.2.265
   Google Scholar
• Analysis, M. Biomaterials and Medical Applications Nanotechnology 2020 Market Analysis. Vol. 3; 2020:2019–2020.
   Google Scholar
• Pinto MP, et al. A molecular stratification of chilean gastric cancer patients with potential clinical applicability. Cancers (Basel). 2020;12:1–14.
   Google Scholar
• Nikalje AP. Nanotechnology and its applications in medicine. Med Chem (Los Angeles). 2015;5. doi:10.4172/2161-0444.1000247
   Google Scholar
• Rizzo LY, Theek B, Storm G, Kiessling F, Lammers T. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol. 2013;24(6):1159–1166. doi:10.1016/j.copbio.2013.02.020
   PubMed Web of Science ®Google Scholar
• Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J. Occup. Med. Toxicol. 2007;2(1):16. doi:10.1186/1745-6673-2-16
   PubMedGoogle Scholar
• Grewal AS, Lather V, Sharma N, et al. Recent updates on nanomedicine based products: current scenario and future opportunities. Appl Clin Res Clin Trials Regul Aff. 2018;5:132–144. doi:10.2174/2213476X05666180611115135
   Google Scholar
• D’Mello SR, Cruz CN, Chen M-L, et al. The evolving landscape of drug products containing nanomaterials in the United States. Nat Nanotechnol. 2017;12:523–529. doi:10.1038/nnano.2017.67
   PubMed Web of Science ®Google Scholar
• Nanomedicine market size worth $350.8 billion by 2025 | CAGR: 11.2%. Available from: https://www.grandviewresearch.com/press-release/global-nanomedicine-market. Accessed December 17, 2020.
   Google Scholar
• Navya PN, Daima HK. Rational engineering of physicochemical properties of nanomaterials for biomedical applications with nanotoxicological perspectives. Nano Converg. 2016;3:1. doi:10.1186/s40580-016-0064-z
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760. doi:10.1038/nnano.2007.387
   PubMed Web of Science ®Google Scholar
• Conde J, Bao C, Tan Y, et al. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumor-associated macrophages and cancer cells. Adv Funct Mater. 2015;25(27):4183–4194. doi:10.1002/adfm.201501283
   PubMed Web of Science ®Google Scholar
• Dickerson EB, Dreaden EC, Huang X, et al. Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice. Cancer Lett. 2008;269(1):57–66. doi:10.1016/j.canlet.2008.04.026
   PubMed Web of Science ®Google Scholar
• Nam J, Son S, Park KS, et al. Cancer nanomedicine for combination cancer immunotherapy. Nat Rev Mater. 2019;4:398–414. doi:10.1038/s41578-019-0108-1
   Web of Science ®Google Scholar
• Turchanin A, Weber D, Büenfeld M, et al. Conversion of self-assembled monolayers into nanocrystalline graphene: structure and electric transport. ACS Nano. 2011;5:3896–3904. doi:10.1021/nn200297n
   PubMedGoogle Scholar
• Moshfegh AZ. Nanoparticle catalysts. J Phys D Appl Phys. 2009;42(23):233001. doi:10.1088/0022-3727/42/23/233001
   Google Scholar
• Yu X, Zhang X, Zou J, et al. Solvent-tunable microstructures of aligned carbon nanotube films. Adv Mater Interfaces. 2016;3(17):1–6. doi:10.1002/admi.201600352
   Google Scholar
• Conde J, et al. Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine. Front Chemist. 2014;2:48.
   PubMed Web of Science ®Google Scholar
• Chen D, Zhao C, Ye J, et al. In situ biosynthesis of fluorescent platinum nanoclusters: toward self-bioimaging-guided cancer theranostics. ACS Appl Mater Interfaces. 2015;7(32):18163–18169. doi:10.1021/acsami.5b05805
   PubMed Web of Science ®Google Scholar
• Zhu C, Zhang H, Li W, et al. Suppress orthotopic colon cancer and its metastasis through exact targeting and highly selective drug release by a smart nanomicelle. Biomaterials. 2018;161:144–153. doi:10.1016/j.biomaterials.2018.01.043
   PubMed Web of Science ®Google Scholar
• Patra JK, et al. Nano based drug delivery systems: recent developments and future prospects 10 technology 1007 nanotechnology 03 chemical sciences 0306 physical chemistry (incl. structural) 03 chemical sciences 0303 macromolecular and materials chemistry 11 medical and health sciences 1115 pharmacology and pharmaceutical sciences 09 engineering 0903 biomedical engineering prof Ueli Aebi, Prof Peter Gehr. J Nanobiotechnology. 2018;16:71.
   PubMed Web of Science ®Google Scholar
• Blum AP, Kammeyer JK, Rush AM, et al. Stimuli-responsive nanomaterials for biomedical applications. J Am Chem Soc. 2015;137(6):2140–2154. doi:10.1021/ja510147n
   PubMed Web of Science ®Google Scholar
• Tasso M, Lago Huvelle MA, Diaz Bessone I, Picco AS. Toxicity Assessment of Nanomaterials. Cham: Springer; 2020:383–446. doi:10.1007/978-3-030-39923-8_13
   Google Scholar
• Buzea C, Pacheco II, Robbie K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases. 2007;2:MR17–MR71. doi:10.1116/1.2815690
   PubMed Web of Science ®Google Scholar
• Sims CM, et al. Redox-active nanomaterials for nanomedicine applications. Nanoscale. 2017;9:15226–15251.
   PubMed Web of Science ®Google Scholar
• Krug HF. Nanosafety research-are we on the right track? Angewandte Chemie - International Edition. 2014;53:12304–12319. doi:10.1002/anie.201403367
   PubMed Web of Science ®Google Scholar
• Kumar V, Lakkaboyana SK, Sharma N, Maitra SS, Hanafiah MM. Nanotoxicology and its remediation. In: Intelligent Nanomaterials for Drug Delivery Applications. Elsevier; 2020:163–178. doi:10.1016/b978-0-12-817830-0.00009-6
   Google Scholar
• Sayes CM. Nanotoxicology: Developing a Responsible Technology. Cham: Springer; 2020:43–55. doi:10.1007/978-3-030-19951-7_4
   Google Scholar
• Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect. 2005;113:823–839. doi:10.1289/ehp.7339
   PubMed Web of Science ®Google Scholar
• Podila R, Brown JM. Toxicity of engineered nanomaterials: a physicochemical perspective. J Biochem Mol Toxicol. 2013;27:50–55. doi:10.1002/jbt.21442
   PubMed Web of Science ®Google Scholar
• Srivastava N, Saxena SK. Opportunities in clinical translation and commercialization of nanomedicine. In: NanoBioMedicine. Singapore: Springer; 2020:501–517. doi:10.1007/978-981-32-9898-9_22
   Google Scholar
• Chapter 1 Nanotechnology and nanomaterials. Stud Interface Sci. 2006;23:1–69.
   Google Scholar
• Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharmaceutical J. 2018;26:64–70. doi:10.1016/j.jsps.2017.10.012
   PubMed Web of Science ®Google Scholar
• Robinson DKR, Huang L, Guo Y, Porter AL. Forecasting innovation pathways (FIP) for new and emerging science and technologies. Technol Forecast Soc Change. 2013;80:267–285. doi:10.1016/j.techfore.2011.06.004
   Web of Science ®Google Scholar
• Roco MC, et al. Innovative and responsible governance of nanotechnology for societal development. In: Nanotechnology Research Directions for Societal Needs in 2020. Netherlands: Springer; 2011:561–617. doi:10.1007/978-94-007-1168-6_14
   Google Scholar
• Oberdörster G, et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. In: Particle and Fibre Toxicology. Vol. 2. 2005:1–35.
   Google Scholar
• Schirmer K. Mechanisms of nanotoxicity. In: Frontiers of Nanoscience. Vol. 7. Elsevier Ltd; 2014:195–221.
   Google Scholar
• Rampado R, Crotti S, Caliceti P, Pucciarelli S, Agostini M. Recent advances in understanding the protein corona of nanoparticles and in the formulation of “Stealthy” Nanomaterials. Front Bioengineer Biotechnol. 2020. doi:10.3389/fbioe.2020.00166
   PubMedGoogle Scholar
• Wright PF. Potential risks and benefits of nanotechnology: perceptions of risk in sunscreens. Med J Aust. 2016;204:369–370. doi:10.5694/mja15.01128
   PubMed Web of Science ®Google Scholar
• Khan AU, Khan M, Cho MH, Khan MM. Selected nanotechnologies and nanostructures for drug delivery, nanomedicine and cure. Bioprocess Biosyst Eng. 2020;43(8):1339–1357. doi:10.1007/s00449-020-02330-8
   PubMed Web of Science ®Google Scholar
• Pruyn SA, Rajabi M, Adeyeye M, Mousa SA. Pharmaceutical applications of water-soluble polymers in nanomedicine and drug delivery. In: The Road from Nanomedicine to Precision Medicine. Jenny Stanford Publishing; 2020:299–334. doi:10.1201/9780429295010-7
   Google Scholar
• Martinelli C, Pucci C, Ciofani G. Nanostructured carriers as innovative tools for cancer diagnosis and therapy. APL Bioengineering. 2019;3:11502. doi:10.1063/1.5079943
   PubMed Web of Science ®Google Scholar
• Bremer-Hoffmann S, Halamoda-Kenzaoui B, Borgos SE. Identification of regulatory needs for nanomedicines. J Interdiscip Nanomedicine. 2018;3:4–15. doi:10.1002/jin2.34
   Google Scholar
• Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33:2373–2387. doi:10.1007/s11095-016-1958-5
   PubMed Web of Science ®Google Scholar
• Oerlemans C, Bult W, Bos M, et al. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm. Res. 2010;27:2569–2589. doi:10.1007/s11095-010-0233-4
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med. 2019;4(3):e10143
   PubMed Web of Science ®Google Scholar
• Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110:13–21. doi:10.1016/j.ygyno.2008.04.033
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36–48. doi:10.1016/j.addr.2012.09.037
   PubMed Web of Science ®Google Scholar
• Yang M, Xie S, Adhikari VP, et al. The synergistic fungicidal effect of low-frequency and low-intensity ultrasound with amphotericin B-loaded nanoparticles on C. albicans in vitro. Int J Pharm. 2018;542:232–241. doi:10.1016/j.ijpharm.2018.03.033
   PubMedGoogle Scholar
• Wang-Gillam A, Li C-P, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545–557. doi:10.1016/S0140-6736(15)00986-1
   PubMed Web of Science ®Google Scholar
• Shegokar R, Müller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010;399:129–139. doi:10.1016/j.ijpharm.2010.07.044
   PubMed Web of Science ®Google Scholar
• van der Meel R, Sulheim E, Shi Y, et al. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14:1007–1017. doi:10.1038/s41565-019-0567-y
   PubMed Web of Science ®Google Scholar
• Hare JI, Lammers T, Ashford MB, et al. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25–38. doi:10.1016/j.addr.2016.04.025
   PubMed Web of Science ®Google Scholar
• Azuaje F. Artificial intelligence for precision oncology: beyond patient stratification. Npj Precis Oncol. 2019;3:1–5. doi:10.1038/s41698-018-0074-x
   PubMedGoogle Scholar
• Ho D, Wang P, Kee T. Artificial intelligence in nanomedicine. Nanoscale Horizons. 2019;4:f365–377. doi:10.1039/C8NH00233A
   PubMedGoogle Scholar
• Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science (80-). 2018;359:1355–1360. doi:10.1126/science.aar7112
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Martin JD, Liu H, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4. doi:10.1038/ncomms3516
   PubMedGoogle Scholar
• Lu J, Liu X, Liao Y-P, et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun. 2017;8. doi:10.1038/s41467-017-01651-9
   Google Scholar
• Mehra NK, Cai D, Kuo L, Hein T, Palakurthi S. Safety and toxicity of nanomaterials for ocular drug delivery applications. Nanotoxicology. 2016;10:836–860. doi:10.3109/17435390.2016.1153165
   PubMed Web of Science ®Google Scholar
• Eleraky NE, Allam A, Hassan SB, Omar MM. Nanomedicine fight against antibacterial resistance: an overview of the recent pharmaceutical innovations. Pharmaceutics. 2020;12:1–51. doi:10.3390/pharmaceutics12020142
   Web of Science ®Google Scholar
• Alavi M, Webster TJ. Nano liposomal and cubosomal formulations with platinum-based anticancer agents: therapeutic advances and challenges. Nanomedicine. 2020;15:2399–2410. doi:10.2217/nnm-2020-0199
   PubMedGoogle Scholar
• Alavi M, Varma RS. Overview of novel strategies for the delivery of anthracyclines to cancer cells by liposomal and polymeric nanoformulations. Int J Biol Macromol. 2020;164:2197–2203. doi:10.1016/j.ijbiomac.2020.07.274
   PubMed Web of Science ®Google Scholar
• Wang C, Yu Y, Irfan M, et al. Rational design of DNA framework-based hybrid nanomaterials for anticancer drug delivery. Small. 2020;16:1–9. doi:10.1002/smll.202002578
   Google Scholar
• Prasad M, Lambe UP, Brar B, et al. Nanotherapeutics: an insight into healthcare and multi-dimensional applications in medical sector of the modern world. Biomed Pharmacother. 2018;97:1521–1537. doi:10.1016/j.biopha.2017.11.026
   PubMed Web of Science ®Google Scholar
• Alavi M, Karimi N. Ultrasound assisted-phytofabricated Fe3O4 NPs with antioxidant properties and antibacterial effects on growth, biofilm formation, and spreading ability of multidrug resistant bacteria. Artif Cells Nanomedicine Biotechnol. 2019;47:2405–2423. doi:10.1080/21691401.2019.1624560
   PubMed Web of Science ®Google Scholar
• Alavi M, Rai M. Recent progress in nanoformulations of silver nanoparticles with cellulose, chitosan, and alginic acid biopolymers for antibacterial applications. Appl Microbiol Biotechnol. 2019;103:8669–8676. doi:10.1007/s00253-019-10126-4
   PubMed Web of Science ®Google Scholar
• Alavi M, Jabari E, Jabbari E. Functionalized carbon-based nanomaterials and quantum dots with antibacterial activity: a review. Expert Rev Anti Infec Thert. 2020;1–10. doi:10.1080/14787210.2020.1810569
   Google Scholar
• Szakal C, Roberts SM, Westerhoff P, et al. Measurement of nanomaterials in foods: integrative consideration of challenges and future prospects. ACS Nano. 2014;8:3128–3135. doi:10.1021/nn501108g
   PubMed Web of Science ®Google Scholar
• Radomska A, Leszczyszyn J, Radomski MW. The nanopharmacology and nanotoxicology of nanomaterials: new opportunities and challenges. Adv Clin Exp Med. 2016;25:151–162. doi:10.17219/acem/60879
   PubMedGoogle Scholar
• Anuje M, Sivan A, Khot VM, Pawaskar PN. Cellular interaction and toxicity of nanostructures. In: Nanomedicines for Breast Cancer Theranostics. Elsevier; 2020:193–243. doi:10.1016/b978-0-12-820016-2.00010-0
   Google Scholar
• Sanjay SS. Precautions to avoid consequences leading to nanotoxification. In: Nanoparticles in Medicine. Singapore: Springer;2020:201–220. doi:10.1007/978-981-13-8954-2_8
   Google Scholar
• Cataldi M, Vigliotti C, Mosca T, Cammarota M, Capone D. Emerging role of the spleen in the pharmacokinetics of monoclonal antibodies, nanoparticles and exosomes. Int J Mol Sci. 2017;18:1249. doi:10.3390/ijms18061249
   PubMed Web of Science ®Google Scholar
• Ibrahim K, Al-Mutary M, Bakhiet A, Khan H. Histopathology of the liver, kidney, and spleen of mice exposed to gold nanoparticles. Molecules. 2018;23:1848. doi:10.3390/molecules23081848
   PubMed Web of Science ®Google Scholar
• Kumar A, Kumar P, Anandan A, et al. Engineered nanomaterials: knowledge gaps in fate, exposure, toxicity, and future directions. J Nanomater. 2014;2014:1–16. doi:10.1155/2014/130198
   Google Scholar
• De Matteis V. Exposure to inorganic nanoparticles: routes of entry, immune response, biodistribution and in vitro/in vivo toxicity evaluation. Toxics. 2017;5:29. doi:10.3390/toxics5040029
   PubMedGoogle Scholar
• Oberdörster G, Kuhlbusch TAJ. In vivo effects: methodologies and biokinetics of inhaled nanomaterials. NanoImpact. 2018;10:38–60. doi:10.1016/j.impact.2017.10.007
   Web of Science ®Google Scholar
• Shah JN, Shah AP, Shah HJ, Sutariya VB. Biointeractions of Nanomaterials. Biointeractions of Nanomaterials. CRC Press; 2014. doi:10.1201/b17191
   Google Scholar
• Qiao R, Jia Q, Hüwel S, et al. Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier. ACS Nano. 2012;6:3304–3310. doi:10.1021/nn300240p
   PubMed Web of Science ®Google Scholar
• Busquets M, Espargaró A, Sabaté R, Estelrich J. Magnetic nanoparticles cross the blood-brain barrier: when physics rises to a challenge. Nanomaterials. 2015;5:2231–2248. doi:10.3390/nano5042231
   Web of Science ®Google Scholar
• Thangadurai TD, Manjubaashini N, Thomas S, Maria HJ. Fundamentals of Nanostructures. Cham: Springer; 2020:29–45. doi:10.1007/978-3-030-26145-0_3
   Google Scholar
• Bergin IL, Witzmann FA. Nanoparticle toxicity by the gastrointestinal route: evidence and knowledge gaps. Int J Biomed Nanosci Nanotechnol. 2013;3:163. doi:10.1504/IJBNN.2013.054515
   Google Scholar
• Zhou X, Liu Y, Wang X, Li X, Xiao B. Effect of particle size on the cellular uptake and anti-inflammatory activity of oral nanotherapeutics. Colloids Surfaces B Biointerfaces. 2020;187:110880. doi:10.1016/j.colsurfb.2020.110880
   PubMed Web of Science ®Google Scholar
• Sahu SC, Casciano DA. Nanotoxicity: From in vivo and in vitro Models to Health Risks. 2009. doi:10.1002/9780470747803
   Google Scholar
• Fernández-Bertólez N, Costa C, Bessa MJ, et al. Assessment of oxidative damage induced by iron oxide nanoparticles on different nervous system cells. Mutat Res Genet Toxicol Environ Mutagen. 2019;845:402989. doi:10.1016/j.mrgentox.2018.11.013
   PubMed Web of Science ®Google Scholar
• Dhawan A, Anderson D, Shanker R. Nanotoxicology: Experimental and Computational Perspectives. 2017.
   Google Scholar
• Onoue S, Yamada S, Chan K. Nanodrugs: pharmacokinetics and safety. Int J Nanomedicine. 2014;9:1025. doi:10.2147/IJN.S38378
   PubMed Web of Science ®Google Scholar
• Fard JK, Jafari S, Eghbal MA. A review of molecular mechanisms involved in toxicity of nanoparticles. Adv Pharm Bull. 2015;5:447–454. doi:10.15171/apb.2015.061
   PubMed Web of Science ®Google Scholar
• Zhao H, Li L, Zhan H, Chu Y, Sun B. Mechanistic understanding of the engineered nanomaterial-induced toxicity on kidney. J Nanomater. 2019;2019:1–12. doi:10.1155/2019/2954853
   Web of Science ®Google Scholar
• Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245–313.
   PubMed Web of Science ®Google Scholar
• Chen Q, Moghaddas S, Hoppel CL, Lesnefsky EJ. Ischemic defects in the electron transport chain increase the production of reactive oxygen species from isolated rat heart mitochondria. Am J Physiol - Cell Physiol. 2008;294:460–467. doi:10.1152/ajpcell.00211.2007
   PubMed Web of Science ®Google Scholar
• Johnston HJ, Hutchison G, Christensen FM, et al. A review of the in vivo and in vitro toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity. Crit Rev Toxicol. 2010;40:328–346. doi:10.3109/10408440903453074
   PubMed Web of Science ®Google Scholar
• Sukhanova A, Bozrova S, Sokolov P, et al. Dependence of nanoparticle toxicity on their physical and chemical properties. Nanoscale Res Lett. 2018;13:1–21. doi:10.1186/s11671-018-2457-x
   PubMed Web of Science ®Google Scholar
• Kumar A, Aileen Senapati V, Dhawan A. Chapter 4: protocols for in vitro and in vivo toxicity assessment of engineered nanoparticles. In: Issues in Toxicology. Vol. 2018. 2018:94–132.
   Google Scholar
• Johnston LJ, Gonzalez-Rojano N, Wilkinson KJ, Xing B. Key challenges for evaluation of the safety of engineered nanomaterials. NanoImpact. 2020;18:100219. doi:10.1016/j.impact.2020.100219
   Web of Science ®Google Scholar
• Gamboa JM, Leong KW. In vitro and in vivo models for the study of oral delivery of nanoparticles. Adv Drug Deliv Rev. 2013;65:800–810. doi:10.1016/j.addr.2013.01.003
   PubMed Web of Science ®Google Scholar
• Lee J, Lilly GD, Doty RC, Podsiadlo P, Kotov NA. In vitro toxicity testing of nanoparticles in 3D cell culture. Small. 2009;5.
   Google Scholar
• Kumar V, Kumari A, Guleria P, Yadav SK. Evaluating the toxicity of selected types of nanochemicals. Rev Environ Contam Toxicol. 2012;215:39–121. doi:10.1007/978-1-4614-1463-6_2
   PubMed Web of Science ®Google Scholar
• Das R, Leo BF, Murphy F. The toxic truth about carbon nanotubes in water purification: a perspective view. Nanoscale Res Lett. 2018;13:183. doi:10.1186/s11671-018-2589-z
   PubMed Web of Science ®Google Scholar
• Tomalia DA, Nixon LS, Hedstrand DM. Engineering critical nanoscale design parameters (CNDPs): A strategy for developing effective nanomedicine therapies and assessing quantitative nanoscale structure-activity relationships (QNSARs). In: Pharmaceutical Applications of Dendrimers. Elsevier; 2019:3–47. doi:10.1016/B978-0-12-814527-2.00001-9
   Google Scholar
• Vetten MA, Gulumian M. Interference of gold nanoparticles with in vitro endotoxin detection assays. Curr Nanosci. 2018. doi:10.2174/1573413715666181212120013
   Google Scholar
• Ostermann M, Sauter A, Xue Y, et al. Label-free impedance flow cytometry for nanotoxicity screening. Sci. Rep. 2020;10:142. doi:10.1038/s41598-019-56705-3
   PubMedGoogle Scholar
• Palacios‐Hernandez T, Diaz‐Diestra DM, Nguyen AK, et al. Cytotoxicity, cellular uptake and apoptotic responses in human coronary artery endothelial cells exposed to ultrasmall superparamagnetic iron oxide nanoparticles. J. Appl. Toxicol. 2020;40:918–930. doi:10.1002/jat.3953
   PubMedGoogle Scholar
• Shah J, Bhagat S, Singh S. Standard biological assays to estimate nanoparticle toxicity and biodistribution. In: Nanotoxicity. Vols. 71–104. Elsevier; 2020. doi:10.1016/b978-0-12-819943-5.00004-x
   Google Scholar
• Sehgal SN, Camardo JS, Scarola JA, Maida BT. Rapamycin (sirolimus, rapamune). In: Current Opinion in Nephrology and Hypertension. Vol. 4. 1995:482–487.
   Google Scholar
• Karabasz A, Szczepanowicz K, Cierniak A, Bereta J, Bzowska M. In vitro toxicity studies of biodegradable, polyelectrolyte nanocapsules. Int J Nanomedicine. 2018;13:5159–5172. doi:10.2147/IJN.S169120
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cao X, Liang T, Tong Z. Acid/light dual-responsive biodegradable polymeric nanocarriers for efficient intracellular drug delivery. Polym Bull. 2019;76:1775–1792. doi:10.1007/s00289-018-2470-3
   Google Scholar
• Su S, Kang PM. Systemic review of biodegradable nanomaterials in nanomedicine. Nanomaterials. 2020;10(4):656. doi:10.3390/nano10040656
   Web of Science ®Google Scholar
• Ilinskaya AN, Dobrovolskaia MA. Nanoparticles and the blood coagulation system. Part II: safety concerns. Nanomedicine. 2013;8:969–981. doi:10.2217/nnm.13.49
   PubMed Web of Science ®Google Scholar
• Sulheim E, et al. Cytotoxicity of poly(Alkyl cyanoacrylate) nanoparticles. International Journal of Molecular Sciences. 2017;18(11). doi:10.3390/ijms18112454
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee YM. Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(ε-caprolactone) as novel anticancer drug carriers. Biomaterials. 2001;22:1697–1704. doi:10.1016/S0142-9612(00)00292-1
   PubMed Web of Science ®Google Scholar
• Hurst HE, Martin MD. Toxicology. In Pharmacology and Therapeutics for Dentistry. Seventh. Elsevier; 2017:603–620. doi:10.1016/B978-0-323-39307-2.00040-0
   Google Scholar
• Oberdörster G, Stone V, Donaldson K. Toxicology of nanoparticles: A historical perspective. In: Nanotoxicology. Vol. 1. 2007:2–25.
   Google Scholar
• Spoo W. Concepts and terminology. In: Clinical Veterinary Toxicology. Elsevier; 2004:2–7. doi:10.1016/b0-32-301125-x/50004-2
   Google Scholar
• Rodallec A, Benzekry S, Lacarelle B, Ciccolini J, Fanciullino R. Pharmacokinetics variability: why nanoparticles are not just magic-bullets in oncology. Crit Rev Oncol Hematol. 2018;129:1–12. doi:10.1016/j.critrevonc.2018.06.008
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. In: Molecular Pharmaceutics. Vol. 5. Mol Pharm; 2008:496–504.
   Google Scholar
• Nel AE. Implementation of alternative test strategies for the safety assessment of engineered nanomaterials. J Intern Med. 2013;274:561–577. doi:10.1111/joim.12109
   PubMed Web of Science ®Google Scholar
• Fadeel B, Farcal L, Hardy B, et al. Advanced tools for the safety assessment of nanomaterials. Nat Nanotechnol. 2018;13:537–543. doi:10.1038/s41565-018-0185-0
   PubMed Web of Science ®Google Scholar
• Romeo D, Salieri B, Hischier R, Nowack B, Wick P. An integrated pathway based on in vitro data for the human hazard assessment of nanomaterials. Environ Int. 2020;137:105505. doi:10.1016/j.envint.2020.105505
   PubMedGoogle Scholar
• Gioria S, Caputo F, Urbán P, et al. Are existing standard methods suitable for the evaluation of nanomedicines: some case studies. Nanomedicine. 2018;13:539–554. doi:10.2217/nnm-2017-0338
   PubMed Web of Science ®Google Scholar
• Mirshafiee V, Jiang W, Sun B, Wang X, Xia T. Facilitating translational nanomedicine via predictive safety assessment. Mol Ther. 2017;25:1522–1530. doi:10.1016/j.ymthe.2017.03.011
   PubMedGoogle Scholar
• Quarta A, Piccirillo C, Mandriota G, Di Corato R. Nanoheterostructures (NHS) and their applications in nanomedicine: focusing on in vivo studies. Materials (Basel). 2019;12:1–37. doi:10.3390/ma12010139
   Google Scholar
• Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 2002;22:1452–1458. doi:10.1161/01.ATV.0000030360.72503.56
   PubMed Web of Science ®Google Scholar
• Cicha I, Chauvierre C, Texier I, et al. From design to the clinic: practical guidelines for translating cardiovascular nanomedicine. Cardiovasc. Res. 2018;114:1714–1727. doi:10.1093/cvr/cvy219
   PubMed Web of Science ®Google Scholar
• Serra A, Fratello M, Cattelani L, et al. Transcriptomics in toxicogenomics, part III: data modelling for risk assessment. Nanomaterials. 2020;10:1–26. doi:10.3390/nano10040708
   Google Scholar
• Dutta A, Dubey T, Singh KK, Anand A. SpliceVec: distributed feature representations for splice junction prediction. Comput Biol Chem. 2018;74:434–441. doi:10.1016/j.compbiolchem.2018.03.009
   PubMedGoogle Scholar
• Furxhi I, Murphy F, Mullins M, Arvanitis A, Poland CA. Practices and trends of machine learning application in nanotoxicology. Nanomaterials. 2020;10:1–32. doi:10.3390/nano10010116
   Google Scholar
• Thomas DG, Gaheen S, Harper SL, et al. ISA-TAB-nano: a specification for sharing nanomaterial research data in spreadsheet-based format. BMC Biotechnol. 2013;13:2. doi:10.1186/1472-6750-13-2
   PubMed Web of Science ®Google Scholar
• Eriksson L, Johansson E. Multivariate design and modeling in QSAR. Chemom Intell Lab Syst. 1996;34:1–19. doi:10.1016/0169-7439(96)00023-8
   Web of Science ®Google Scholar
• Horev-Azaria L, Kirkpatrick CJ, Korenstein R, et al. Predictive toxicology of cobalt nanoparticles and ions: comparative in vitro study of different cellular models using methods of knowledge discovery from data. Toxicol. Sci. 2011;122:489–501. doi:10.1093/toxsci/kfr124
   PubMed Web of Science ®Google Scholar
• Gajewicz A, Puzyn T, Odziomek K, et al. Decision tree models to classify nanomaterials according to the DF4nanoGrouping scheme. Nanotoxicology. 2018;12:1–17. doi:10.1080/17435390.2017.1415388
   PubMed Web of Science ®Google Scholar
• Hund-Rinke K, Herrchen M, Schlich K, Schwirn K, Völker D. Test strategy for assessing the risks of nanomaterials in the environment considering general regulatory procedures. Environ Sci Eur. 2015;27:1–12. doi:10.1186/s12302-015-0053-6
   Google Scholar
• Gioria S, et al. Are existing standard methods suitable for the evaluation of nanomedicines: some case studies. In: Nanomedicine. Vol. 13. 2018:539–554.
   Google Scholar
• You DJ, Lee HY, Bonner JC. Macrophages: first innate immune responders to nanomaterials. In: Molecular and Integrative Toxicology. Springer Science+Business Media B.V; 2020:15–34. doi:10.1007/978-3-030-33962-3_2
   Google Scholar
• Zhang T, Gaffrey MJ, Qian WJ, Thrall BD. Oxidative stress and redox modifications in nanomaterial–cellular interactions. In: Molecular and Integrative Toxicology. Springer Science+Business Media B.V; 2020:127–148. doi:10.1007/978-3-030-33962-3_8
   Google Scholar
• Zhu M, Nie G, Meng H, et al. Physicochemical properties determine nanomaterial cellular uptake, transport, and fate. Acc. Chem. Res. 2013;46:622–631. doi:10.1021/ar300031y
   PubMed Web of Science ®Google Scholar
• Hou WC, Westerhoff P, Posner JD. Biological accumulation of engineered nanomaterials: a review of current knowledge. Environmental Sciences: Processes and Impacts. 2013;15:103–122.
   PubMed Web of Science ®Google Scholar
• Zhu M, Perrett S, Nie G. Understanding the particokinetics of engineered nanomaterials for safe and effective therapeutic applications. Small. 2013;9:1619–1634. doi:10.1002/smll.201201630
   PubMedGoogle Scholar
• Zamay GS, Zamay TN, Lukyanenko KA, Kichkailo AS. Aptamers increase biocompatibility and reduce the toxicity of magnetic nanoparticles used in biomedicine. Biomedicines. 2020;8:59. doi:10.3390/biomedicines8030059
   PubMedGoogle Scholar
• Lundqvist M, Stigler J, Elia G, et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. U. S. A. 2008;105:14265–14270. doi:10.1073/pnas.0805135105
   PubMed Web of Science ®Google Scholar
• Gatoo MA, Naseem S, Arfat MY, et al. Physicochemical properties of nanomaterials: implication in associated toxic manifestations. Biomed Res Int. 2014;2014:1–8. doi:10.1155/2014/498420
   Web of Science ®Google Scholar
• Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science (80-). 2006;311:622–627. doi:10.1126/science.1114397
   PubMed Web of Science ®Google Scholar
• Xia T, Kovochich M, Brant J, et al. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett. 2006;6:1794–1807. doi:10.1021/nl061025k
   PubMed Web of Science ®Google Scholar
• Suen WLL, Chau Y. Size-dependent internalisation of folate-decorated nanoparticles via the pathways of clathrin and caveolae-mediated endocytosis in ARPE-19 cells. J Pharm Pharmacol. 2014;66:564–573. doi:10.1111/jphp.12134
   PubMed Web of Science ®Google Scholar
• Jiang W, Kim BYS, Rutka JT, Chan WCW. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol. 2008;3:145–150. doi:10.1038/nnano.2008.30
   PubMed Web of Science ®Google Scholar
• Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surfaces B Biointerfaces. 2008;66:274–280. doi:10.1016/j.colsurfb.2008.07.004
   PubMed Web of Science ®Google Scholar
• Hoshino A, Fujioka K, Oku T, et al. Physicochemical properties and cellular toxicity of nanocrystal quantum dots depend on their surface modification. Nano Lett. 2004;4:2163–2169. doi:10.1021/nl048715d
   Web of Science ®Google Scholar
• Goodman CM, McCusker CD, Yilmaz T, Rotello VM. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem. 2004;15:897–900. doi:10.1021/bc049951i
   PubMed Web of Science ®Google Scholar
• Saxena RK, Williams W, Mcgee JK, et al. Enhanced in vitro and in vivo toxicity of poly-dispersed acid-functionalized single-wall carbon nanotubes. Nanotoxicology. 2007;1:291–300. doi:10.1080/17435390701803110
   Web of Science ®Google Scholar
• Pietroiusti A, Massimiani M, Fenoglio I, et al. Low doses of pristine and oxidized single-wall carbon nanotubes affect mammalian embryonic development. ACS Nano. 2011;5:4624–4633. doi:10.1021/nn200372g
   PubMed Web of Science ®Google Scholar
• Gurr JR, Wang ASS, Chen CH, Jan KY. Ultrafine titanium dioxide particles in the absence of photoactivation can induce oxidative damage to human bronchial epithelial cells. Toxicology. 2005;213:66–73. doi:10.1016/j.tox.2005.05.007
   PubMed Web of Science ®Google Scholar
• Griffitt RJ, Luo J, Gao J, Bonzongo JC, Barber DS. Effects of particle composition and species on toxicity of metallic nanomaterials in aquatic organisms. Environ Toxicol Chem. 2008;27:1972–1978. doi:10.1897/08-002.1
   PubMed Web of Science ®Google Scholar
• Sharifi S, et al. Toxicity of nanomaterials. Chem Soc Rev. 2016;41:2323–2343.
   Google Scholar
• Halamoda-Kenzaoui B, Holzwarth U, Roebben G, Bogni A, Bremer-Hoffmann S. Mapping of the available standards against the regulatory needs for nanomedicines. Wiley Interdiscip Rev Nanomedicine Nanobiotechnology. 2019;11:e1531. doi:10.1002/wnan.1531
   PubMed Web of Science ®Google Scholar
• Patel K, Patel J, Patel M, Rajput G, Patel H. Introduction to hyphenated techniques and their applications in pharmacy. Pharm Methods. 2010;1:2. doi:10.4103/2229-4708.72222
   PubMedGoogle Scholar
• Clogston JD, Hackley VA, Prina-Mello A, et al. Sizing up the next generation of nanomedicines. Pharm Res. 2020;37. doi: 10.1007/s11095-019-2736-y
   Google Scholar
• Hole P. Particle Tracking Analysis (PTA). In: Characterization of Nanoparticles: Measurement Processes for Nanoparticles. Elsevier; 2019:79–96. doi:10.1016/B978-0-12-814182-3.00007-9
   Google Scholar
• Hu Y, Crist RM, Clogston JD. The utility of asymmetric flow field-flow fractionation for preclinical characterization of nanomedicines. Anal Bioanal Chem. 2020;412:425–438. doi:10.1007/s00216-019-02252-9
   PubMedGoogle Scholar
• Sahin E, Roberts CJ. Size-exclusion chromatography with multi-angle light scattering for elucidating protein aggregation mechanisms. Methods Mol Biol. 2012;899:403–423.
   PubMedGoogle Scholar
• Klein M, Menta M, Dacoba TG, et al. Advanced nanomedicine characterization by DLS and AF4-UV-MALS: application to a HIV nanovaccine. J. Pharm. Biomed. Anal. 2020;179:113017. doi:10.1016/j.jpba.2019.113017
   PubMed Web of Science ®Google Scholar
• Filipe V, Hawe A, Jiskoot W. Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res. 2010;27:796–810. doi:10.1007/s11095-010-0073-2
   PubMed Web of Science ®Google Scholar
• Gruia F, Parupudi A, Polozova A. Practical considerations for detection and characterization of sub-micron particles in protein solutions by nanoparticle tracking analysis. PDA J Pharm Sci Technol. 2015;69:427–439. doi:10.5731/pdajpst.2015.01051
   PubMedGoogle Scholar
• Zattoni A, Rambaldi DC, Reschiglian P, et al. Asymmetrical flow field-flow fractionation with multi-angle light scattering detection for the analysis of structured nanoparticles. J Chromatogr A. 2009;1216:9106–9112. doi:10.1016/j.chroma.2009.06.037
   PubMedGoogle Scholar
• Chamieh J, Cottet H. Size-based characterisation of nanomaterials by Taylor dispersion analysis. In: Colloid and Interface Science in Pharmaceutical Research and Development. 2014. doi:10.1016/B978-0-444-62614-1.00009-0
   Google Scholar
• Chamieh J, Leclercq L, Martin M, et al. Limits in size of taylor dispersion analysis: representation of the different hydrodynamic regimes and application to the size-characterization of cubosomes. Anal. Chem. 2017;89(24):13487–13493. doi:10.1021/acs.analchem.7b03806
   PubMed Web of Science ®Google Scholar
• Cottet H, Biron JP, Martin M. Taylor dispersion analysis of mixtures. Anal. Chem. 2007;79(23):9066–9073. doi:10.1021/ac071018w
   PubMedGoogle Scholar
• Urban DA, Milosevic AM, Bossert D, et al. Taylor dispersion of inorganic nanoparticles and comparison to dynamic light scattering and transmission electron microscopy. Colloids Interface Sci. Commun. 2018;22:29–33. doi:10.1016/j.colcom.2017.12.001
   Google Scholar
• Hulse WL, Gray J, Forbes RT. Evaluating the inter and intra batch variability of protein aggregation behaviour using Taylor dispersion analysis and dynamic light scattering. Int. J. Pharm. 2013;453(2):351–357. doi:10.1016/j.ijpharm.2013.05.062
   PubMedGoogle Scholar
• Weatherall E, Willmott GR. Applications of tunable resistive pulse sensing. Analyst. 2015;140(10):3318–3334. doi:10.1039/c4an02270j
   PubMed Web of Science ®Google Scholar
• Pal AK, Aalaei I, Gadde S, et al. High resolution characterization of engineered nanomaterial dispersions in complex media using tunable resistive pulse sensing technology. ACS Nano. 2014;8(9):9003–9015. doi:10.1021/nn502219q
   PubMedGoogle Scholar
• Pei Y, Vogel R, Minelli C. Tunable resistive pulse sensing (TRPS). In: Characterization of Nanoparticles: Measurement Processes for Nanoparticles. 2019. doi:10.1016/B978-0-12-814182-3.00009-2
   Google Scholar
• Mørk M, Pedersen S, Botha J, Lund SM, Kristensen SR. Preanalytical, analytical, and biological variation of blood plasma submicron particle levels measured with nanoparticle tracking analysis and tunable resistive pulse sensing. Scand. J. Clin. Lab. Invest. 2016;76(5):349–360. doi:10.1080/00365513.2016.1178801
   PubMed Web of Science ®Google Scholar
• Su QP, et al. CTCF-mediated chromatin structures dictate the spatiotemporal propagation of replication foci. bioRxiv. 2019. doi:10.1101/525915
   Google Scholar
• Pentyala S, Muller J, Tumillo T, et al. A novel point-of-care biomarker recognition method: validation by detecting marker for diabetic nephropathy. Diagnostics. 2015;5:177–188. doi:10.3390/diagnostics5020177
   Google Scholar
• Guzman JMCC, Hsu SM, Chuang HS. Colorimetric diagnostic capillary enabled by size sieving in a porous hydrogel. Biosensors. 2020;10(10):130. doi:10.3390/bios10100130
   PubMedGoogle Scholar
• Nelemans LC, Gurevich L. Drug delivery with polymeric nanocarriers-cellular uptake mechanisms. Materials (Basel). 2020;13:1–21. doi:10.3390/ma13020366
   Google Scholar
• Dvornikov A, Malacrida L, Gratton E. The diver microscope for imaging in scattering media. Methods Protoc. 2019;2:1–12. doi:10.3390/mps2020053
   Google Scholar
• El-Hamadi M, Schätzlein AG. Nanoparticles in medical imaging. Fundam Pharm Nanosci. 2013;6:543–566.
   Google Scholar
• Herranz F, Almarza E, Rodríguez I, et al. The application of nanoparticles in gene therapy and magnetic resonance imaging. Microsc. Res. Tech. 2011;74:577–591. doi:10.1002/jemt.20992
   PubMedGoogle Scholar
• Sohal IS, O’Fallon KS, Gaines P, Demokritou P, Bello D. Ingested engineered nanomaterials: state of science in nanotoxicity testing and future research needs. Part Fibre Toxicol. 2018;15. doi:10.1186/s12989-018-0265-1
   PubMedGoogle Scholar
• Kermanizadeh A, Pojana G, Gaiser BK, et al. In vitro assessment of engineered nanomaterials using a hepatocyte cell line: cytotoxicity, pro-inflammatory cytokines and functional markers. Nanotoxicology. 2013;7:301–313. doi:10.3109/17435390.2011.653416
   PubMed Web of Science ®Google Scholar
• Applications B, Pirzada M, Altintas Z. Nanomaterials for Healthcare. Sensors. 2019;19:5311–5367. doi:10.3390/s19235311
   PubMedGoogle Scholar
• Holzinger M, Goff Le A, Cosnier S. Nanomaterials for biosensing applications: a review. Front Chem. 2014;2:1–10. doi:10.3389/fchem.2014.00063
   Google Scholar
• Shi J, Votruba AR, Farokhzad OC, et al. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010;10:3223–3230. doi:10.1021/nl102184c
   PubMed Web of Science ®Google Scholar
• Mohammadi MR, Nojoomi A, Mozafari M, et al. Nanomaterials engineering for drug delivery: a hybridization approach. J Mater Chem B. 2017;5:3995–4018. doi:10.1039/C6TB03247H
   PubMed Web of Science ®Google Scholar
• Lim M, Badruddoza AZM, Firdous J, et al. Engineered nanodelivery systems to improve dna vaccine technologies. Pharmaceutics. 2020;12:1–29. doi:10.3390/pharmaceutics12010030
   Google Scholar
• Chen J, Guo Z, Tian H, Chen X. Production and clinical development of nanoparticles for gene delivery. Mol Ther - Methods Clin Dev. 2016;3:16023. doi:10.1038/mtm.2016.23
   PubMed Web of Science ®Google Scholar
• Hasan A, Morshed M, Memic A, et al. Nanoparticles in tissue engineering: applications, challenges and prospects. Int J Nanomedicine. 2018;13:5637–5655. doi:10.2147/IJN.S153758
   PubMed Web of Science ®Google Scholar
• Fries CN, Curvino EJ, Chen J-L, et al. Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health. Nat. Nanotechnol. 2020. doi:10.1038/s41565-020-0739-9
   PubMedGoogle Scholar
• Semaeva E, Tenstad O, Skavland J, et al. Access to the spleen microenvironment through lymph shows local cytokine production, increased cell flux, and altered signaling of immune cells during lipopolysaccharide-induced acute inflammation. J. Immunol. 2010;184:4547–4556. doi:10.4049/jimmunol.0902049
   PubMed Web of Science ®Google Scholar
• Doak SH, Liu Y, Chen C. Genotoxicity and Cancer. In: Adverse Effects of Engineered Nanomaterials: Exposure, Toxicology, and Impact on Human Health. 2nd ed. Elsevier Inc; 2017:423–445. doi:10.1016/B978-0-12-809199-9.00018-5
   Google Scholar
• Kristensen BW, Noer H, Gramsbergen JB, Zimmer J, Noraberg J. Colchicine induces apoptosis in organotypic hippocampal slice cultures. Brain Res. 2003;964:264–278. doi:10.1016/S0006-8993(02)04080-5
   PubMedGoogle Scholar
• Bhatia S, Bhatia S. Nanoparticles types, classification, characterization, fabrication methods and drug delivery applications. In: Natural Polymer Drug Delivery Systems. Springer International Publishing; 2016:33–93. doi:10.1007/978-3-319-41129-3_2
   Google Scholar